
In adults with obesity or overweight plus comorbidities but without T2D once-weekly tirzepatide was associated with significant and durable weight loss vs placebo.

In adults with obesity or overweight plus comorbidities but without T2D once-weekly tirzepatide was associated with significant and durable weight loss vs placebo.

Methods proven to prevent ASCVD may fall short in certain populations if the impacts of SDOH are not closely monitored. The ACC/AHA provide considerations for 7 health domains.

Your daily dose of clinical news you may have missed.

Your daily dose of clinical news you may have missed.

Is BMI or body fat a better estimate of obesity?; spoiler: older women do drink ETOH; USPSTF vs ACC/AHA; plus no more opioids for LBP and a primer on migraine meds.

Your daily dose of clinical news you may have missed.

Children and adolescents who reported facing more racial discrimination had a higher BMI and waist circumference, according to new data.

In Israel, where 60% of adults are overweight, new research prompts investigators to suggest that % body fat should replace BMI as the gold standard measure of obesity.

Underestimation of weight status increased while overestimation decreased during the last 2 decades, according to results from a study of over 745 000 adolescents.

The importance of avoiding judgement, monitoring behavior, and cardiovascular risk prevention in primary care are discussed, here.

Early intervention is crucial to help prevent complications in patients with obesity and type 2 diabetes. Two experts explain more, here.

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Listen to 2 obesity experts discuss the impact of the COVID-19 pandemic on obesity-related type 2 diabetes.

Retatrutide, survodutide, orforglipron. The 3 new GLP-1 agonist-based AOMs showed weight loss of up to 20% and are well worth watching.

ADA 2023: Weight loss with the combination GLP-1/GIP/glucagon receptor agonist was as high as 30% in study participants who received the highest dose.

Your daily dose of clinical news you may have missed.

ADA 2023. Once-daily oral semaglutide 50 mg induced 15.1% weight loss in adults with overweight or obesity without type 2 diabetes vs placebo.

Your daily dose of clinical news you may have missed.

ADA 2023: The investigational oral GLP-1 RA resulted in weight loss comparable to injectable GLP-1 RA formulations and requires no food or water restrictions.

ADA 2023: Among survodutide-treated participants in a phase 2 study, more than half lost more than 50% of baseline bodyweight, reported PI Carel le Roux, MBChB, PhD.

ADA 2023: SURMOUNT-2 findings show tirzepatide is associated with greater weight loss in adults with T2D than any other treatment studied to date.

Type 2 diabetes will continue to comprise more than 90% of this population and obesity will be the primary driver, according to Global Burden of Disease researchers.

ADA 2023. Retatrutide, an investigational triple GLP-1/GIP/glucagon agonist, may provide benefits in liver fibrosis and obesity as well as in glycemic control.

Early intervention is important to reduce the risk for complications for patients with obesity and type 2 diabetes. Two obesity experts explain more, here.

Listen to 2 obesity experts discuss and analyze the role of insulin resistance in type 2 diabetes and obesity.